WO2001031029A3 - Gene de la sphingosine kinase humaine - Google Patents

Gene de la sphingosine kinase humaine Download PDF

Info

Publication number
WO2001031029A3
WO2001031029A3 PCT/EP2000/009498 EP0009498W WO0131029A3 WO 2001031029 A3 WO2001031029 A3 WO 2001031029A3 EP 0009498 W EP0009498 W EP 0009498W WO 0131029 A3 WO0131029 A3 WO 0131029A3
Authority
WO
WIPO (PCT)
Prior art keywords
sphingosine kinase
kinase gene
human sphingosine
nucleic acid
recombinant
Prior art date
Application number
PCT/EP2000/009498
Other languages
English (en)
Other versions
WO2001031029A2 (fr
Inventor
Janet Allen
Mark Gosink
Alirio J Melendez
Laszlo Takacs
Original Assignee
Warner Lambert Co
Janet Allen
Mark Gosink
Alirio J Melendez
Laszlo Takacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Janet Allen, Mark Gosink, Alirio J Melendez, Laszlo Takacs filed Critical Warner Lambert Co
Priority to AU10202/01A priority Critical patent/AU1020201A/en
Priority to JP2001533164A priority patent/JP2003512072A/ja
Priority to CA002389127A priority patent/CA2389127A1/fr
Priority to MXPA02004294A priority patent/MXPA02004294A/es
Priority to BR0015138-6A priority patent/BR0015138A/pt
Priority to EP00971299A priority patent/EP1228221A2/fr
Publication of WO2001031029A2 publication Critical patent/WO2001031029A2/fr
Publication of WO2001031029A3 publication Critical patent/WO2001031029A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)

Abstract

L'invention concerne un gène de type 1 de la sphingosine kinase. Plus précisément, l'invention concerne un acide nucléique de ladite sphingosine kinase purifié ou isolé, ou une séquence complémentaire de celle-ci, ou des fragments de celle-ci. L'invention concerne des oligonucléotides, des polypeptides recombinants, des vecteurs recombinants, des cellules hôtes recombinantes comprenant ledit acide nucléique, ainsi que la production d'anticorps, des méthodes de criblages, des oligonucléotides antisens et des mammifères 'knock out'.
PCT/EP2000/009498 1999-10-28 2000-10-27 Gene de la sphingosine kinase humaine WO2001031029A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU10202/01A AU1020201A (en) 1999-10-28 2000-10-27 Human sphingosine kinase gene
JP2001533164A JP2003512072A (ja) 1999-10-28 2000-10-27 ヒトスフィンゴシンキナーゼ遺伝子
CA002389127A CA2389127A1 (fr) 1999-10-28 2000-10-27 Gene de la sphingosine kinase humaine
MXPA02004294A MXPA02004294A (es) 1999-10-28 2000-10-27 Gen de esfingosina cinasa de humano.
BR0015138-6A BR0015138A (pt) 1999-10-28 2000-10-27 Gene da esfingosina quinase humana
EP00971299A EP1228221A2 (fr) 1999-10-28 2000-10-27 Gene de la sphingosine kinase humaine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16230799P 1999-10-28 1999-10-28
US60/162,307 1999-10-28
US18052500P 2000-02-07 2000-02-07
US60/180,525 2000-02-07

Publications (2)

Publication Number Publication Date
WO2001031029A2 WO2001031029A2 (fr) 2001-05-03
WO2001031029A3 true WO2001031029A3 (fr) 2002-02-28

Family

ID=26858638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009498 WO2001031029A2 (fr) 1999-10-28 2000-10-27 Gene de la sphingosine kinase humaine

Country Status (7)

Country Link
EP (1) EP1228221A2 (fr)
JP (1) JP2003512072A (fr)
AU (1) AU1020201A (fr)
BR (1) BR0015138A (fr)
CA (1) CA2389127A1 (fr)
MX (1) MXPA02004294A (fr)
WO (1) WO2001031029A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
US6858427B2 (en) * 2000-02-14 2005-02-22 Genentech, Inc. Sphingosine kinases
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
JP2004500903A (ja) * 2000-06-28 2004-01-15 メドベット・サイエンス・プロプライエタリー・リミテッド 治療的分子変種およびその使用方法
US6610534B2 (en) * 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
US6858383B2 (en) 2000-12-22 2005-02-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
AU2003216076A1 (en) * 2002-01-17 2003-09-02 Children's Hospital And Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
AU2007329759B2 (en) 2006-10-27 2013-05-30 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
CN109355269B (zh) * 2018-10-21 2020-03-24 北京双因生物科技有限公司 鞘氨醇激酶1及其融合蛋白及其用途
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054963A2 (fr) * 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 proteines secretees humaines
WO1999061581A2 (fr) * 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Clonage, expression et procedes d'utilisation de la sphingosine kinase
WO2000052173A2 (fr) * 1999-03-02 2000-09-08 Nps Allelix Corp. Homologues de sphingosine kinase humaine clones
WO2000055332A2 (fr) * 1999-03-18 2000-09-21 Incyte Pharmaceuticals, Inc. Regulateur de la phosphorylation intracellulaire
WO2000070028A1 (fr) * 1999-05-13 2000-11-23 Johnson & Johnson Research Pty. Limited Enzyme sphingosine kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054963A2 (fr) * 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 proteines secretees humaines
WO1999061581A2 (fr) * 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Clonage, expression et procedes d'utilisation de la sphingosine kinase
WO2000052173A2 (fr) * 1999-03-02 2000-09-08 Nps Allelix Corp. Homologues de sphingosine kinase humaine clones
WO2000055332A2 (fr) * 1999-03-18 2000-09-21 Incyte Pharmaceuticals, Inc. Regulateur de la phosphorylation intracellulaire
WO2000070028A1 (fr) * 1999-05-13 2000-11-23 Johnson & Johnson Research Pty. Limited Enzyme sphingosine kinase

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BANNO Y ET AL: "Evidence for the presence of multiple forms of Sph kinase in human platelets", BIOCHEMICAL JOURNAL,PORTLAND PRESS, LONDON,GB, vol. 335, 15 October 1998 (1998-10-15), pages 301 - 304, XP000956301, ISSN: 0264-6021 *
DATABASE EM_EST EMBL; 30 June 1999 (1999-06-30), NATIONAL CANCER INSTITUTE, CGAP: "wj30d06.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone IMAGE:2404331 3' similar to TR:O88886 O88886 SPHINGOSINE KINASE. ;, mRNA sequence.", XP002167579 *
DATABASE EM_EST EMBL; 6 March 1997 (1997-03-06), HILLIER L ET AL.: "zr45f08.r1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:666375 5', mRNA sequence.", XP002167580 *
DATABASE EM_EST EMBL; 9 February 1995 (1995-02-09), SUDO K ET AL.: "Human fetal-lung cDNA 5'-end sequence.", XP002167581 *
DATABASE EM_SY EMBL; 16 August 1995 (1995-08-16), PETERS H ET AL.: "Cloning vector pcDNA3ZEO DNA", XP002167582 *
KOHAMA ET AL: "Molecular Cloning and Functional Characterization of Murine Sphingosine Kinase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 37, 11 September 1998 (1998-09-11), pages 23722 - 23728, XP002150781, ISSN: 0021-9258 *
MELENDEZ A J ET AL.: "Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution", GENE, vol. 251, no. 1, June 2000 (2000-06-01), pages 19 - 26, XP004202082, ISSN: 0378-1119 *
PITSON S M ET AL.: "Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes", BIOCHEMICAL JOURNAL, vol. 350, no. PART 02, 1 September 2000 (2000-09-01), pages 429 - 441, XP000946990, ISSN: 0264-6021 *

Also Published As

Publication number Publication date
JP2003512072A (ja) 2003-04-02
EP1228221A2 (fr) 2002-08-07
AU1020201A (en) 2001-05-08
WO2001031029A2 (fr) 2001-05-03
MXPA02004294A (es) 2002-10-31
CA2389127A1 (fr) 2001-05-03
BR0015138A (pt) 2002-07-16

Similar Documents

Publication Publication Date Title
WO2001031029A3 (fr) Gene de la sphingosine kinase humaine
IL161769A0 (en) Anbtimicrobial polypeptides from pseudoplectania nigrella
WO2001023575A3 (fr) Homologues du gene wuschel (wus)
WO2000032756A3 (fr) Des diacylglycerol acyltransfease vegetale
WO2000066739A3 (fr) Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci
IL135688A0 (en) Human checkpoint kinase, hcds1, compositions and methods
WO2002048329A3 (fr) Caspase 3 derivee d'une membrane, compositions contenant cette caspase et procedes d'utilisation associes
WO2000052136A3 (fr) Enzymes de glycosylation humaines
BR9709658A (pt) Isolamento de genes de biossíntese para pseudo-oligossacarídeos a partir de streptomyces glaucescens gla o e sua aplicação
WO1999049058A3 (fr) Enzyme de biosynthese du tryptophane
WO2000004167A3 (fr) Genes codant des proteines d'assimilation du sulfate
WO2000014207A3 (fr) Farnesyltransferases vegetales
WO1998011234A3 (fr) Proteines kinases humaines
EP1849868A3 (fr) Défensines végétales
WO2000028036A3 (fr) Facteurs de resistance a la maladie
WO1999047689A3 (fr) Inhibiteurs des proteines d'apoptose dans des vegetaux
WO2000047723A3 (fr) Nouvelles proteines
WO2000022100A3 (fr) Proteine disulfure isomerase d'arthropode
WO1999054436A3 (fr) Acides nucleiques et proteines de genes de type insuline derives de c. elegans, et leurs utilisations
WO1999048486A3 (fr) Genes de cycline de cellules vegetales
WO1999028446A3 (fr) Enzymes biosynthetiques a acides amines ramifies
WO2001016325A3 (fr) Proteines de reproduction destinees aux plantes
WO1999021880A3 (fr) Enzymes vegetales de biosynthese a chaine ramifiee d'acide amine
WO2001000662A3 (fr) Utilisation de polypeptides fgh-8 humains comme agents neurotrophiques
WO1999057285A3 (fr) Saccharose phosphate synthase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 533164

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2389127

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/004294

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000971299

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000971299

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000971299

Country of ref document: EP